Targeting treatment resistance in chronic lymphocytic leukaemia
New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of…
New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of…
On December 1, 2023, the Food and Drug Administration granted accelerated approval to pirtobrutinib for adults…
Personalised treatment for the most common form of adult leukaemia helps patients survive for longer…
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukaemia…
A newly constructed map of the landscape of genetic changes in chronic lymphocytic leukaemia (CLL),…
Chronic lymphocytic leukaemia (CLL) is one of the most common blood cancers in adults. The…
Young patients with chronic lymphocytic leukaemia (CLL) can enjoy long remissions on the drug ibrutinib, but must stay on it indefinitely to…
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world. New research…
Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in…
Death from infection – the leading cause of death for patients with a common type…